3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Triple Negative Breast Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
5
Breast Neoplasms
5
Head and Neck Neoplasms
4
Carcinoma, Renal Cell
4
Turcot syndrome
3
Melanoma
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hodgkin Disease
2
Glioblastoma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Advanced Endometrial Cancer
2
Tongue Neoplasms
1
To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma
1
Thyroid Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Squamous NSCLC
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Interventions
pembrolizumab
1
enfortumab vedotin
1
Tablets
1
Single Person
1
Rosuvastatin Calcium
1
Memantine
1
Exercise Therapy
1
Exercise
1
Acupuncture Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Peripheral Nervous System Diseases
×
pembrolizumab
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled